Impact Partnership Wealth LLC Buys 1,539 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Impact Partnership Wealth LLC raised its stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) by 8.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 19,078 shares of the company’s stock after purchasing an additional 1,539 shares during the period. Impact Partnership Wealth LLC’s holdings in Adaptive Biotechnologies were worth $114,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. The Manufacturers Life Insurance Company raised its position in Adaptive Biotechnologies by 5.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,834 shares of the company’s stock worth $177,000 after purchasing an additional 2,710 shares during the period. Vontobel Holding Ltd. grew its stake in shares of Adaptive Biotechnologies by 30.8% during the third quarter. Vontobel Holding Ltd. now owns 17,000 shares of the company’s stock valued at $87,000 after buying an additional 4,000 shares during the last quarter. SG Americas Securities LLC grew its stake in shares of Adaptive Biotechnologies by 11.7% during the fourth quarter. SG Americas Securities LLC now owns 45,944 shares of the company’s stock valued at $275,000 after buying an additional 4,799 shares during the last quarter. JTC Employer Solutions Trustee Ltd bought a new position in shares of Adaptive Biotechnologies during the third quarter valued at approximately $26,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd grew its stake in shares of Adaptive Biotechnologies by 29.5% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 25,576 shares of the company’s stock valued at $131,000 after buying an additional 5,826 shares during the last quarter. Institutional investors own 99.17% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Piper Sandler upped their target price on Adaptive Biotechnologies from $6.00 to $7.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. BTIG Research upped their target price on Adaptive Biotechnologies from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th.

Adaptive Biotechnologies Stock Down 1.7 %

Shares of NASDAQ:ADPT opened at $7.99 on Friday. Adaptive Biotechnologies Co. has a 52-week low of $2.28 and a 52-week high of $8.33. The stock has a market cap of $1.18 billion, a P/E ratio of -5.96 and a beta of 1.47. The business’s 50 day moving average is $6.31 and its 200 day moving average is $5.26.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.